Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sibille

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Therapie|November 1, 1993
[Critical value of bilirubin in the selection of healthy volunteers in for phase I]V Olagnier, M Sibille, D Vital Durand, et al.
European Journal of Clinical Pharmacology|January 1, 1997
Critical limits to define a lab adverse event during phase I studies: a study in 1134 subjectsM Sibille, V Bresson, A Janin, et al.
Presse Medicale (Paris, France : 1983)|June 11, 1988
[Myalgia induced by sotalol. A case]I Kieffer, A Dellinger, M Sibille, et al.
La Revue De Medecine Interne|January 1, 1991
[Plea for a reasonable interpretation of low TSH]D Vital Durand, M Adnaoui, Y Barbier, et al.
European Journal of Clinical Pharmacology|January 1, 1995
Upper limit of plasma alanine amino transferase during phase I studiesM Sibille, L G Lassonery, A Janin, et al.
La Revue De Medecine Interne|January 1, 1990
[Diagnostic significance of low thyrotropin in internal medicine]M Adnaoui, D Vital Durand, Y Barbier, et al.
European Journal of Clinical Pharmacology|April 17, 1999
Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trialsM Sibille, N Deigat, I Durieu, et al.
La Revue De Medecine Interne|January 1, 1997
[Dementia syndrome of recent appearance...]T Zenone, A Revol, I Durieu, et al.
Journal of Clinical Pharmacology|November 15, 2000
Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteersP N Zannikos, S Rohatagi, B K Jensen, et al.
Clinical Drug Investigation|August 14, 2016
Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir SystemY Le Roux, M L Borg, M Sibille, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Therapie|November 1, 1993
[Critical value of bilirubin in the selection of healthy volunteers in for phase I]V Olagnier, M Sibille, D Vital Durand, et al.
European Journal of Clinical Pharmacology|January 1, 1997
Critical limits to define a lab adverse event during phase I studies: a study in 1134 subjectsM Sibille, V Bresson, A Janin, et al.
Presse Medicale (Paris, France : 1983)|June 11, 1988
[Myalgia induced by sotalol. A case]I Kieffer, A Dellinger, M Sibille, et al.
La Revue De Medecine Interne|January 1, 1991
[Plea for a reasonable interpretation of low TSH]D Vital Durand, M Adnaoui, Y Barbier, et al.
European Journal of Clinical Pharmacology|January 1, 1995
Upper limit of plasma alanine amino transferase during phase I studiesM Sibille, L G Lassonery, A Janin, et al.
La Revue De Medecine Interne|January 1, 1990
[Diagnostic significance of low thyrotropin in internal medicine]M Adnaoui, D Vital Durand, Y Barbier, et al.
European Journal of Clinical Pharmacology|April 17, 1999
Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trialsM Sibille, N Deigat, I Durieu, et al.
La Revue De Medecine Interne|January 1, 1997
[Dementia syndrome of recent appearance...]T Zenone, A Revol, I Durieu, et al.
Journal of Clinical Pharmacology|November 15, 2000
Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteersP N Zannikos, S Rohatagi, B K Jensen, et al.
Clinical Drug Investigation|August 14, 2016
Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir SystemY Le Roux, M L Borg, M Sibille, et al.
Pageof 4